This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
Historically nephrology is a specialty that has been criticized for it’s inability to produce high quality randomized controlled clinical trials designed to answer a specific question. So, when the Lancet publishes the results of a clinical trial in the field it is worth taking note.
Their have been hints that the combination of Pip/Tazo and Vanco could be nephrotoxic. Here is the first prospective (but not randomized) data looking at this question.